卵巢功能储备正常者拮抗剂方案COH使用过程中添加高纯度人绝经促性腺激素对IVF-ET妊娠结局的影响

doi:10.13481/j.1671-587x.20180527

Abstract

Abstract: Objective:To investigate the influence of high-purity human menopausal gonadotrophin (HP-hMG) added in different periods of antagonist program COH in the pregnancy outcom of in vitro fertilization-embryo transplantation (IVF-ET) of the patients with normal ovarian function reserve,and to clarify the possible mechanism. Methods:A totol of 142 patients aged from 25 to 40 years old with normal ovarian function underwent IVF treatment were selected.According to the timing of HP-hMG addition,they were divided into early addition group (HP-hMG was added on the first day) and middel and latel addition group (HP-hMG was added on the 6th day).The pregnancy outcomes of the patients were analyzed. Results:Compared with early addition group, the estradiol(E2) level on the day of human chorimic gonadotropin(HCG) injection in middle and late addition group was significantly increased (P=0.042) and the progesterone(P) level on the day of HCG injection was significantly decreased(P=0.016), the number of follicles with diameter > 16 mm (P=0.035) and the number of follicles with diameter > 18 mm(P=0.026) were increased.Compared with early addition group,the rate of mature follicles in middle and late addition group was increased (P=0.006),the rate of high quality embroy was increased (P=0.001),and the cumulative pregnancy rate was increased (P=0.040). Conclusion:The addition of HP-hMG at middle and late follicular phase can improve the pregnancy outcome in the patients with normal ovarition function reserve under went antagonist program COH.

Key words: high purity human menopausal gonadotropin, antagonist regime, in vitro fertilization-embryo transplantation, pregnancy outcome

CLC Number:

R711.75

MA Yalan, ZHANG Xin, LI Dandan, ZHOU He, FANG Shujia, XU Ying, ZHENG Lianwen. Influence of high-purity human menopausal gonadotropin added in process of antagonist program COH in IVF-ET pregnancy outcome in patients with normal ovarian function reserve[J].Journal of Jilin University(Medicine Edition), 2018, 44(05): 1036-1040.

References

[1] 张娟,董丽,凌秀凤.拮抗剂方案在体外受精-胚胎移植周期中的应用[J].中国妇幼健康研究,2016,27(4):543-545.
[2] 蔡素芬, 张顺吉, 李晓峰,等.人高纯度人绝经期促性腺激素在促排卵治疗中的应用研究[J].生殖医学杂志,2016,25(12):1074-1078.
[3] Al-Inany HG,Abou-Setta AM,Aboulghar MA,et al.Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH:a meta-analysis[J].Reprod Biomed Online,2008,16(1):81-88.
[4] Platteau P,Nyboe Andersen A,Loft A,et al.Highly purified HMG versus recombinant FSH for ovarian stimulation in IVF cycle[J].Reprod Biomed Online,2008,17(2):190-198.
[5] Coomarasamy A, afnan M,Cheema D,et al.Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocal in IVF or ICSI treatment:a systemmatic review and meta-analysis[J].Hum Reprod,2008,23(2):310-315.
[6] Hill MJ Levens ED,Levy G,Ryan ME,et al.The Use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age:a systematic review and meta-analysis[J].Fertil Steril,2012,97(5):1108-1114.
[7] Drakakis P, Loutradis D,Kallianidis K,et al.Small doses of LH activity are needed early in ovarian stimulation for better quality oocytes in IVF-ET[J].Eur J Obstet Gynecol Reprod Biol,2005,121(1):77-80.
[8] 谭欣,贺贞,左涛,等.血清和卵泡液中雌激素孕激素水及其比值与获卵数和妊娠结局的关系[J].实用妇产科杂志,2014, 30(3):216-219.
[9] Nardo LG,Sabatini L,Rai R,et al.Pinopode expression during human implantation[J].Eur Obstec Gyneol Reprod Biol,2002,101(2):104-108.
[10] Azem F,Lessing JB,Maleov M,et al. Does high serum progesterone level on the day of human chorionic gonadotropin administration affect pregnancy rate after intracytoplasmic sperm injection and embryo transfer?[J].Gynecol Endocrinol,2008,24(7):368-372.
[11] Mochtar MH.Recombinant luteinizing hurmone(rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles[J]. Cochrane Database Syst,2007(2):388.
[12] Hugues JN. Impact of ‘LH activity’ supplementation on serum progesterone levels during controlled ovarian stimulation:a systematic review[J]. Hum Reprod,2012, 27(1):232-243.
[13] De Geyter C,De Geyter M,Huber PR.et al.progesterone serum levels during the follicular phase of the menstrual cycle originate from the crosstalk between the ovaries and the adrenal cortex[J].Hum Reprod,2002,17(4):933-939.
[14] Kiliedag EB,Haydardedoglu B,Cok T,et al.Premature progesterone elevation impaires implantation[J]. Hum Reprod,2010,19(3)134-137.
[15] 叶虹, 黄国宁, 裴莉, 等. 控制性超排卵中血清促黄体生成素浓度过低对体外受精-胚胎移植的影响[J]. 实用妇产科杂志,2002, 18(3):154-157.
[16] Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction[J]. Hum Reprod,2000, 15(5):1003-1008.
[17] Fleming R, Lloyd F, Herbert M, et al. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone[J].Hum Reprod, 1998, 13(7):1788-1792.
[18] 田东梅,李亨利,朱明辉,等.卵巢储备正常者COH不同阶段添加高纯度人绝经期促性腺激素对IVF-ET结局的影响[J].生殖与避孕,2016,36(9):769-773.
[19] Sunkara SK, Coomarasamy A, Khalaf YA,et al. Three-arm randomised controlled trial comparing Gonadotrophin Releasing Hormone (GnRH) agonist long regimen versus GnRH agonist short regimen versus GnRH antagonist regimen in women with a history of poor ovarian response undergoing in vitro fertilisation (IVF) treatment:Poor responders intervention trial (PRINT)[J].Reprod Health,2007,4(12):1-9.
[20] Zeynep Ozturk Inal,, Nafiye Yilmaz, Hasan Ali Inal a, Necati Hancerliogullari,Bugra CoskunAre there any differences between antagonist administration on days <6 and=6 of COH on assisted reproductive technique outcomes[J].Chin Med Asso,2017,10(9):1-5.
[21] Arya S,Kupesic-Plavsic S,Mulla ZD,et al.Ovulation induction and controlled ovarian stimulation using letrozole gonadotropin combination:A single center retrospective cohort study[J].Eur Obstet Gynecol Reprod Biol,2017,218:123-128.
[22] Safak Olgan,Peter Humaidan.GnRH antagonist and letrozole co-treatment in diminished ovarian reserve patients:a proof-of-concept study[J].Reproduct Biol,2017,17(6):105-110.
[23] 胡欣,陈国芳,刘超.2型糖尿病合并低促性腺激素性性腺功能减退研究进展[J].中国实用内科杂志,2016,36(1):79-81.
[24] Bleau N, Agdi M, Son W.A comparison of outcomes from in vitro fertilization cycles stimulated with follicle stimulating hormone plus either recombinant luteinizing hormone or human menopausal gonadotropins in subjects treated with long gonadotropin releasing hormone agonist protocols[J].Int J Ferti Steril,2017,11(2):79-84.
[25] 方璐,边疆,郑燕伟,等.体外受精超促排卵治疗中单用促性腺激素和拮抗剂方案临床结局的比较[J].中华生殖与避孕杂志,2017,37(5):357-360.

Influence of high-purity human menopausal gonadotropin added in process of antagonist program COH in IVF-ET pregnancy outcome in patients with normal ovarian function reserve

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 1

Metrics

Comments

Recommended 0